OPRX
OptimizeRx Corporation12.77
-0.41-3.11%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A flags 15-20% contract lag
Q&A quantified a broader client pause—15-20% behind on contracted revenue ex-managed services—with shorter pulses amid MFN uncertainty, extending prepared remarks' softness warning. Management dismissed panic, forecasting mid-year normalization and back-half strength to hit conservative 2026 guide. DAAP subscriptions neared 10% run-rate; exclusive channel partners poached from rivals signal network gains. Mid-tier growth exceeded expectations, filling infra gaps. Debt paydown trumps buybacks. Shorter contracts lag 15-20% now. Investors watch subscription ramp and H1 recovery.
Key Stats
Market Cap
238.04MP/E (TTM)
1277.00Basic EPS (TTM)
0.01Dividend Yield
0%Recent Filings
8-K
Repurchase program authorized
OptimizeRx extended its financing agreement maturity to October 11, 2029, while authorizing a $10 million share repurchase program effective March 12, 2026, through March 15, 2027, funded by cash. Q4 revenue held at $32.2 million with record $12.0 million adjusted EBITDA; full-year revenue hit $109.4 million, up 19%. 2026 guidance: $109-$114 million revenue, $21-$25 million adjusted EBITDA. Volatility may curb spending.
10-Q
Q3 FY2025 results
OptimizeRx posted Q3 revenue of $26.1M, up 22% y/y, driving gross profit to $17.5M at 67% margin—10 points better than last year—while operating income flipped to $2.1M from an $8.6M loss, thanks to no repeat goodwill impairment. Nine-month revenue climbed 29% y/y to $77.2M, with $0.01 diluted EPS matching shares outstanding at 19.0M; cash hit $19.5M after $11.6M operating cash flow, less $138 capex for $11.5M FCF (derived). Debt fell to $28.8M term loan (due 2027 at 12.9%), with covenant compliance. Repaid $2M post-quarter. Customer concentration lingers.
8-K
Q3 revenue up 22%
OptimizeRx posted Q3 revenue of $26.1 million, up 22% year-over-year, with gross profit surging 30% to $17.5 million and Adjusted EBITDA hitting $5.1 million. No goodwill impairment this year. It raised 2025 guidance to $105-109 million revenue and $16-19 million Adjusted EBITDA, plus debuted 2026 targets of $118-124 million revenue. Debt shrinks fast.
8-K
Leadership promotions announced
OptimizeRx appointed Brendan Merrell as COO effective August 18, 2025, with $325,000 base salary and 40% target bonus, while Ed Stelmakh shifts to Chief Financial & Strategic Officer to lead strategy alongside finance. These changes, approved August 15, aim to accelerate the Rule of 40 strategy. Leadership runs deep.
10-Q
Q2 FY2025 results
OptimizeRx flipped to $29.2M revenue in Q2 ended June 30, 2025, up 55% y/y from $18.8M, with gross margin expanding to 63.8% from 62.2%; operating income swung to $3.2M from a $3.7M loss. YTD revenue hit $51.1M, up 33% y/y, but net loss narrowed to $0.7M from $10.9M as stock-based comp fell. Cash climbed to $16.6M on $8.4M operating cash flow, less $0.1M capex for $8.3M FCF; term loan dropped to $29.3M at 13.1% after $5M repayments, covenants met. Debt service eats margins. Customer concentration risks persist.
IPO
Website
Employees
Sector
Industry
DH
Definitive Healthcare Corp.
2.29-0.01
DOCS
Doximity, Inc.
43.80-0.85
DRIO
DarioHealth Corp.
12.05+0.05
GDRX
GoodRx Holdings, Inc.
2.76+0.05
HIMS
Hims & Hers Health, Inc.
36.86+0.61
MCK
McKesson Corporation
809.96-13.05
OMCL
Omnicell, Inc.
44.74+1.47
OMDA
Omada Health, Inc.
14.61+0.02
ONMD
OneMedNet Corp
1.41+0.17
OPK
Opko Health, Inc.
1.31-0.04